Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$337.42 +1.8%	$346.62	$267.83 ▼ $391.29	$182.10B	0.44	2.75 million shs	2.00 million shs
BMY Bristol Myers Squibb	$59.58 +1.8%	$58.48	$42.52 ▼ $62.89	$121.67B	0.26	12.18 million shs	8.45 million shs
JNJ Johnson & Johnson	$231.69 +1.0%	$234.43	$149.04 ▼ $251.71	$557.73B	0.27	8.44 million shs	5.24 million shs
LLY Eli Lilly and Company	$1,041.89 +2.3%	$940.69	$623.78 ▼ $1,133.95	$981.19B	0.48	3.19 million shs	2.70 million shs
MRK Merck & Co., Inc.	$115.86 +2.5%	$115.82	$75.40 ▼ $125.14	$286.15B	0.18	10.87 million shs	7.38 million shs
NVO Novo Nordisk A/S	$44.38 -1.5%	$40.05	$35.12 ▼ $81.44	$198.17B	0.77	21.35 million shs	11.60 million shs
NVS Novartis	$151.85 +0.9%	$150.10	$111.06 ▼ $170.46	$289.74B	0.46	1.99 million shs	965,733 shs
XLV Health Care Select Sector SPDR Fund	$148.15 +0.7%	$146.68	$127.96 ▼ $160.59	$38.83B	0.58	12.77 million shs	7.15 million shs
XPH SPDR S&P Pharmaceuticals ETF	$57.87 +1.1%	$56.10	$39.21 ▼ $60.73	$355.90M	0.61	83,318 shs	16,587 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.25%	-1.45%	-5.31%	-11.70%	+20.57%
BMY Bristol Myers Squibb	+0.37%	+3.64%	-1.20%	-3.10%	+22.18%
JNJ Johnson & Johnson	-0.33%	-0.52%	-0.56%	-7.16%	+49.25%
LLY Eli Lilly and Company	-0.16%	+0.11%	+10.37%	-0.69%	+36.25%
MRK Merck & Co., Inc.	-1.07%	-0.49%	-3.53%	-7.24%	+45.04%
NVO Novo Nordisk A/S	+1.88%	-4.36%	+11.41%	-7.00%	-33.89%
NVS Novartis	+0.03%	+0.47%	-0.35%	-8.17%	+33.95%
XLV Health Care Select Sector SPDR Fund	-0.13%	+0.29%	-0.20%	-6.44%	+9.23%
XPH SPDR S&P Pharmaceuticals ETF	+2.58%	-3.13%	-2.97%	-0.33%	+39.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$337.42 +1.8%	$346.62	$267.83 ▼ $391.29	$182.10B	0.44	2.75 million shs	2.00 million shs
BMY Bristol Myers Squibb	$59.58 +1.8%	$58.48	$42.52 ▼ $62.89	$121.67B	0.26	12.18 million shs	8.45 million shs
JNJ Johnson & Johnson	$231.69 +1.0%	$234.43	$149.04 ▼ $251.71	$557.73B	0.27	8.44 million shs	5.24 million shs
LLY Eli Lilly and Company	$1,041.89 +2.3%	$940.69	$623.78 ▼ $1,133.95	$981.19B	0.48	3.19 million shs	2.70 million shs
MRK Merck & Co., Inc.	$115.86 +2.5%	$115.82	$75.40 ▼ $125.14	$286.15B	0.18	10.87 million shs	7.38 million shs
NVO Novo Nordisk A/S	$44.38 -1.5%	$40.05	$35.12 ▼ $81.44	$198.17B	0.77	21.35 million shs	11.60 million shs
NVS Novartis	$151.85 +0.9%	$150.10	$111.06 ▼ $170.46	$289.74B	0.46	1.99 million shs	965,733 shs
XLV Health Care Select Sector SPDR Fund	$148.15 +0.7%	$146.68	$127.96 ▼ $160.59	$38.83B	0.58	12.77 million shs	7.15 million shs
XPH SPDR S&P Pharmaceuticals ETF	$57.87 +1.1%	$56.10	$39.21 ▼ $60.73	$355.90M	0.61	83,318 shs	16,587 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.25%	-1.45%	-5.31%	-11.70%	+20.57%
BMY Bristol Myers Squibb	+0.37%	+3.64%	-1.20%	-3.10%	+22.18%
JNJ Johnson & Johnson	-0.33%	-0.52%	-0.56%	-7.16%	+49.25%
LLY Eli Lilly and Company	-0.16%	+0.11%	+10.37%	-0.69%	+36.25%
MRK Merck & Co., Inc.	-1.07%	-0.49%	-3.53%	-7.24%	+45.04%
NVO Novo Nordisk A/S	+1.88%	-4.36%	+11.41%	-7.00%	-33.89%
NVS Novartis	+0.03%	+0.47%	-0.35%	-8.17%	+33.95%
XLV Health Care Select Sector SPDR Fund	-0.13%	+0.29%	-0.20%	-6.44%	+9.23%
XPH SPDR S&P Pharmaceuticals ETF	+2.58%	-3.13%	-2.97%	-0.33%	+39.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.48	Hold	$355.19	5.27% Upside
BMY Bristol Myers Squibb	2.37	Hold	$61.31	2.90% Upside
JNJ Johnson & Johnson	2.74	Moderate Buy	$253.04	9.22% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,219.26	17.02% Upside
MRK Merck & Co., Inc.	2.68	Moderate Buy	$128.18	10.63% Upside
NVO Novo Nordisk A/S	2.13	Hold	$65.56	47.72% Upside
NVS Novartis	2.31	Hold	$141.20	-7.01% Downside
XLV Health Care Select Sector SPDR Fund	2.76	Moderate Buy	$148.15	N/A
XPH SPDR S&P Pharmaceuticals ETF	2.63	Moderate Buy	$57.87	N/A

Current Analyst Ratings Breakdown

Latest AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2026	LLY Eli Lilly and Company	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00
5/21/2026	LLY Eli Lilly and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
5/20/2026	AMGN Amgen	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$400.00 ➝ $375.00
5/19/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
5/15/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
5/14/2026	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$432.00 ➝ $427.00
5/13/2026	JNJ Johnson & Johnson	Johnson Rice Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform
5/13/2026	AMGN Amgen	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$410.00 ➝ $390.00
5/13/2026	JNJ Johnson & Johnson	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$265.00
5/12/2026	NVO Novo Nordisk A/S	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
5/7/2026	AMGN Amgen	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$36.75B	4.95	$34.50 per share	9.78	$17.03 per share	19.81
BMY Bristol Myers Squibb	$48.19B	2.52	$8.31 per share	7.17	$9.84 per share	6.06
JNJ Johnson & Johnson	$94.19B	5.92	$14.22 per share	16.29	$33.73 per share	6.87
LLY Eli Lilly and Company	$65.18B	15.05	$25.64 per share	40.63	$33.13 per share	31.45
MRK Merck & Co., Inc.	$65.01B	4.40	$11.59 per share	10.00	$18.60 per share	6.23
NVO Novo Nordisk A/S	$46.80B	4.23	$4.70 per share	9.45	$7.12 per share	6.23
NVS Novartis	$54.53B	5.31	$10.84 per share	14.01	$20.40 per share	7.44
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$7.71B	$14.37	23.48	14.32	3.32	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
BMY Bristol Myers Squibb	$7.05B	$3.56	16.74	9.82	0.17	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.65	26.79	18.42	2.25	21.83%	32.60%	13.29%	7/15/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	37.01	23.56	1.11	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$3.55	32.64	11.85	2.57	13.59%	27.55%	10.73%	8/4/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.26	10.42	12.86	3.94	37.23%	63.31%	22.19%	8/5/2026 (Estimated)
NVS Novartis	$13.98B	$6.98	21.75	15.45	2.64	24.87%	38.82%	15.16%	7/21/2026 (Estimated)
XLV Health Care Select Sector SPDR Fund	N/A	N/A	21.15	N/A	N/A	N/A	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A	N/A	14.28	N/A	N/A	N/A	N/A	N/A	N/A

Latest AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2026	Q1 2026	NVO Novo Nordisk A/S	$0.87	$1.04	+$0.17	$1.69	$10.86 billion	$10.85 billion
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion
4/30/2026	Q1 2026	MRK Merck & Co., Inc.	-$1.47	-$1.28	+$0.19	-$1.72	$15.85 billion	$16.29 billion
4/27/2026	Q1 2026	NVS Novartis	$2.11	$1.99	-$0.12	$1.65	$13.44 billion	$13.52 billion
4/14/2026	Q1 2026	JNJ Johnson & Johnson	$2.68	$2.70	+$0.02	$2.14	$23.60 billion	$24.06 billion
3/31/2026	Q1 2026	NVO Novo Nordisk A/S	N/A	$1.0270	N/A	$1.69	N/A	$10.85 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$10.08	2.99%	+8.27%	70.15%	14 Years
BMY Bristol Myers Squibb	$2.52	4.23%	+1.61%	70.79%	17 Years
JNJ Johnson & Johnson	$5.20	2.24%	+5.25%	60.12%	64 Years
LLY Eli Lilly and Company	$6.92	0.66%	+15.18%	24.58%	11 Years
MRK Merck & Co., Inc.	$3.40	2.93%	+5.75%	95.77%	14 Years
NVO Novo Nordisk A/S	$1.75	3.94%	+21.74%	41.08%	N/A
NVS Novartis	$3.08	2.03%	+5.28%	44.13%	N/A
XLV Health Care Select Sector SPDR Fund	$2.50	1.69%	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	$0.37	0.64%	N/A	N/A	N/A

Latest AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026
4/14/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.23%	5/26/2026	5/26/2026	6/9/2026
3/4/2026	AMGN Amgen	quarterly	$2.52	3.09%	5/15/2026	5/15/2026	6/5/2026
3/2/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.23%	4/2/2026	4/2/2026	5/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	5.65	1.26	1.01
BMY Bristol Myers Squibb	2.10	1.42	1.28
JNJ Johnson & Johnson	0.46	1.03	0.77
LLY Eli Lilly and Company	1.26	1.50	1.10
MRK Merck & Co., Inc.	1.02	1.30	1.06
NVO Novo Nordisk A/S	0.59	0.79	0.56
NVS Novartis	0.96	0.85	0.65
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BMY Bristol Myers Squibb	76.41%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVO Novo Nordisk A/S	11.54%
NVS Novartis	13.12%
XLV Health Care Select Sector SPDR Fund	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.85%
BMY Bristol Myers Squibb	0.05%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%
NVO Novo Nordisk A/S	0.07%
NVS Novartis	0.01%
XLV Health Care Select Sector SPDR Fund	N/A
XPH SPDR S&P Pharmaceuticals ETF	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	31,500	539.68 million	535.10 million	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.47 billion	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable
XLV Health Care Select Sector SPDR Fund	N/A	262.11 million	N/A	Not Optionable
XPH SPDR S&P Pharmaceuticals ETF	N/A	6.15 million	N/A	Not Optionable

AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Headlines

Recent News About These Companies

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

May 19 at 4:19 PM | 247wallst.com

Trump to announce discount drug pricing expansion, White House official says

May 18 at 12:47 PM | reuters.com

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

April 3, 2026 | zacks.com

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

March 30, 2026 | zacks.com

SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0610

March 23, 2026 | msn.com

US and China clash over fentanyl and tariffs at global drugs meeting

March 9, 2026 | reuters.com

These 5 Undervalued ETFs Could Be Bargains Right Now

February 26, 2026 | 247wallst.com

XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning

February 18, 2026 | 247wallst.com

XPH's 29% Run Looks Tempting, But The 5y Chart Is A Warning

February 18, 2026 | 247wallst.com

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

January 29, 2026 | zacks.com

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

January 28, 2026 | zacks.com

XPH: Healthcare Dashboard For January

January 16, 2026 | seekingalpha.com

State Street® SPDR® S&P® Pharmaceuticals ETF

January 11, 2026 | markets.businessinsider.com

3 Undervalued ETFs to Buy Before 2026

December 10, 2025 | zacks.com

Pharma ETF (XPH) Hits a New 52-Week High

December 9, 2025 | zacks.com

US and UK agree zero-tariffs on pharmaceuticals

December 1, 2025 | news.sky.comN

US, UK to agree to zero tariffs on pharmaceuticals, announcement expected, sources say

December 1, 2025 | reuters.com

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

November 28, 2025 | zacks.com

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

November 27, 2025 | zacks.com

Big pharma hits a record high as FDA picks new drug regulator

November 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Company Descriptions

Amgen NASDAQ:AMGN

$337.42 +5.85 (+1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$337.32 -0.10 (-0.03%)

As of 07:52 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Bristol Myers Squibb NYSE:BMY

$59.58 +1.04 (+1.78%)

Closing price 03:59 PM Eastern

Extended Trading

$59.56 -0.03 (-0.05%)

As of 07:49 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Johnson & Johnson NYSE:JNJ

$231.69 +2.37 (+1.03%)

Closing price 03:59 PM Eastern

Extended Trading

$231.50 -0.19 (-0.08%)

As of 07:52 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$1,041.89 +23.02 (+2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$1,043.00 +1.11 (+0.11%)

As of 07:54 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$115.86 +2.86 (+2.53%)

Closing price 03:59 PM Eastern

Extended Trading

$120.15 +4.29 (+3.70%)

As of 07:54 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S NYSE:NVO

$44.38 -0.69 (-1.52%)

Closing price 03:59 PM Eastern

Extended Trading

$44.45 +0.07 (+0.15%)

As of 07:54 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novartis NYSE:NVS

$151.84 +1.40 (+0.93%)

Closing price 03:59 PM Eastern

Extended Trading

$152.88 +1.04 (+0.68%)

As of 07:49 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$148.15 +1.02 (+0.69%)

Closing price 04:10 PM Eastern

Extended Trading

$148.38 +0.23 (+0.16%)

As of 07:52 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

SPDR S&P Pharmaceuticals ETF NYSEARCA:XPH

$57.87 +0.62 (+1.08%)

As of 04:10 PM Eastern

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Earnings

Compare Dividends

Latest AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMGN, BMY, LLY, XLV, JNJ, MRK, NVS, NVO, and XPH Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools